Dry Age-Related Macular Degeneration - Epidemiology Forecast - 2034

Key Highlights

• Dry AMD has the potential to progress to geographic atrophy, a stage characterized by irreversible vision loss caused by the depletion of crucial retinal components such as retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris in the macula.
• Although this condition is not uncommon in clinical practice, it can go undetected until the atrophy involves the fovea and affects central vision. Patients do not consult an ophthalmologist until they notice visual impairment due to foveal involvement.
• Multimodal imaging is advised for evaluating geographic atrophy presence and progression. Optical coherence tomography (OCT) stands out among these modalities as it proves valuable in identifying progression biomarkers in patients with intermediate AMD and in assessing the macula while quantifying geographic atrophy lesions.
• Detecting early biomarkers signaling the risk of progression from intermediate AMD to vision-threatening late stages is crucial for personalized management and timely intervention.
• According to estimates, the US accounted for around 20 million prevalent cases of dry AMD in 2023, and these cases are expected to increase during the forecast period
• In 2023, the geographical atrophy accounted for nearly 955,000 cases in EU4 and the UK.
• According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.

The " Dry AMD -Epidemiology - 2034" report delivers an in-depth understanding of dry AMD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Dry AMD Disease Understanding and Treatment Algorithm

Dry AMD Overview

By 1965, the terminology surrounding AMD had gained widespread acceptance, with the condition classified into three clinical stages: early, intermediate, and advanced AMD. The earliest clinical sign of early AMD is the presence of drusen (>63 and =125 µm in diameter), which hampers the patient's ability to adapt to changes in illumination. However, the most substantial central visual loss occurs in the intermediate and advanced stages, with advanced AMD encompassing geographic atrophy and neovascular AMD. Geographic atrophy is characterized by a gradual deterioration of the macular RPE, photoreceptor layer, and choroidal capillaries, resulting in progressive vision loss over time. Diagnosis requires thorough eye examinations, and management strategies focus on slowing disease progression and optimizing remaining vision. Despite efforts, a cure for advanced dry AMD remains elusive, emphasizing the critical need for ongoing research to develop effective treatments for this debilitating condition.

Dry AMD Diagnosis

Diagnosing dry AMD typically involves a comprehensive eye examination, during which an ophthalmologist or optometrist evaluates the retina for characteristic signs of the condition. These signs may include the presence of drusen, small yellow deposits beneath the retina, and changes in pigmentation. Advanced imaging techniques such as optical coherence tomography (OCT) and fundus autofluorescence imaging may also be employed to assess the extent of retinal degeneration. Early detection is crucial in managing dry AMD, as it allows for timely intervention to slow disease progression and preserve vision.

Dry AMD Epidemiology

The dry AMD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of AMD, stage-specific prevalent cases of AMD, total prevalent cases of geographic atrophy, total prevalent cases of dry AMD, total diagnosed prevalent cases of dry AMD, age-specific cases of early and intermediate AMD, age-specific cases of geographic atrophy, geographic atrophy cases by visual impairment in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The total prevalent cases of AMD in the 7MM was nearly 68,347,000 in 2023.
• Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period.
• Several researchers reported a declining prevalence of late AMD in the United States when comparing data from the 2000s with data gathered in previous decades.
• Although there are relatively equal numbers of neovascular AMD and geographic atrophy in White populations, late AMD is less common among Japanese people than among white subjects. In Asian countries, although the prevalence of geographic atrophy is low, the rapidly aging population means that geographic atrophy is becoming an increasingly urgent and unmet medical need. The difference in the prevalence of AMD among races is also partly owing to genetic background; for example, some single nucleotide polymorphisms (SNPs) in complement factors are associated with AMD in Caucasians.

KOL Views

To keep up with current trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the dry AMD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Retinal Specialist, ophthalmologist, eye specialist, and others.

The analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Institute for Saint John’s Health Center in California, Byers Eye Institute, McPherson Eye Research Institute, Retina specialist at Providence Saint John’s Health Center, Department of Ophthalmology, Ophthalmic Consultants etc., were contacted.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of dry AMD, explaining its causes, signs, symptoms, and pathogenesis.
• Comprehensive insight into the epidemiology segments and forecasts, and disease progressionhas been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Dry AMD Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise cases of dry AMD

Dry AMD Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Dry AMD Epidemiology Segmentation

Dry AMD Report Assessment

• Current Diagnostic Practices

FAQs

• What are the disease risk, burdens, and unmet needs of dry AMD? What will be the growth opportunities across the 7MM concerning the patient population with dry AMD?
• What is the historical and forecasted dry AMD patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which age group of dry AMD has a high patient share?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the age-specific dry AMD prevalence cases in varying geographies over the coming years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.